RENO-30 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Reno-30, and what generic alternatives are available?
Reno-30 is a drug marketed by Bracco and is included in one NDA.
The generic ingredient in RENO-30 is diatrizoate meglumine. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the diatrizoate meglumine profile page.
Summary for RENO-30
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 32 |
Patent Applications: | 890 |
Formulation / Manufacturing: | see details |
DailyMed Link: | RENO-30 at DailyMed |
Pharmacology for RENO-30
Drug Class | Radiographic Contrast Agent |
Mechanism of Action | X-Ray Contrast Activity |
US Patents and Regulatory Information for RENO-30
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bracco | RENO-30 | diatrizoate meglumine | SOLUTION;URETERAL | 010040-021 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |